As cancer treatment shifts from broad chemotherapy to highly personalized therapies, drug development in oncology is also evolving.
Sarah Alwardt, PhD
Advertisement
Articles by Sarah Alwardt, PhD
Improvements and greater familiarity with artificial intelligence will lead to systems of checks and balances that will create trust and fulfill the promise of computer-assisted precision medicine.
Advertisement
Latest Updated Articles
AI Will Converge With Physician-Directed CareJanuary 5th 2019
Advertisement
Advertisement
Trending on OncLive
1
HERIZON-GEA-01 PD-L1 Subgroup Data Support Zanidatamab Combo as a New Frontline SOC in HER2+ GEA
2
TALAPRO-3 Shows Talazoparib Plus Enzalutamide Improves rPFS in HRR-Altered mCSPC
3
Selinexor Plus Ruxolitinib Yields Superior Spleen Responses, OS Signal in JAK Inhibitor–Naïve Myelofibrosis
4
Dr Eads on Early Data for CDH17-Directed CAR T-Cell Therapy in R/R GI Cancers
5